• Explore /
  • Poster
  • / A phase II study of regorafenib plus sintilimab as salvage-line treatments in non–MSI-H metastatic colorectal cancer (mCRC).

A phase II study of regorafenib plus sintilimab as salvage-line treatments in non–MSI-H metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Rui Liu

Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China

Rui Liu , Zhi Ji , Xia Wang , Le Zhang , Yuchong Yang , Tao Ning , Shaohua Ge , Hongli Li , Ming Bai , Ting Deng , Yi Ba

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT04745130

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3562)

DOI

10.1200/JCO.2023.41.16_suppl.3562

Abstract #

3562

Poster Bd #

262

Abstract Disclosures

Similar Posters

First Author: Miao Wang

First Author: Jiwon Lee

First Author: Wensi Zhao

First Author: Qin Xu